Cardiol Therapeutics Inc.
CRDLDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
CardiolRx Phase 3 Est. Readout
Estimated primary completion for CardiolRx trial (NCT06708299) in Recurrent Pericarditis. Topline data typically follows completion by weeks to months.
SourceHow CRDL's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CardiolRx | Phase 3 | Acute Myocarditis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cardiol Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Cardiol Therapeutics Inc.'s (CRDL) pipeline across Phase 3. Its lead program is CardiolRx (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cardiol Therapeutics Inc.'s next FDA catalyst?→
Cardiol Therapeutics Inc.'s (CRDL) next tracked catalyst is a Phase 3 expected September 21, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRDL biotech catalysts?→
Add CRDL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cardiol Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.